Royalty Pharma (RPRX) Free Cash Flow (2019 - 2026)
Royalty Pharma (RPRX) free cash flow from Jun 30, 2019 to Mar 31, 2026. The TTM Royalty Pharma (RPRX) free cash flow is $2.61B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Free Cash Flow
Quarterly Free Cash Flow
Royalty Pharma (RPRX) Free Cash Flow CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -3.28% |
| 3 Years TTM | -1.31% |
| 5 Years TTM | +4.56% |
| All Time TTM | +11.75% |
Annual Free Cash Flow change of Royalty Pharma (RPRX)
| Year | Free Cash Flow | Change |
|---|---|---|
| 2026 | $718M | -71.15% |
| 2025 | $2.49B | -10.08% |
| 2024 | $2.77B | -7.32% |
| 2023 | $2.99B | +39.36% |
| 2022 | $2.14B | +6.27% |
| 2021 | $2.02B | -0.84% |
| 2020 | $2.03B | +22.04% |
| 2019 | $1.67B | +3.02% |
| 2018 | $1.62B | N/A |
Comparison Royalty Pharma (RPRX) five years free cash flow CAGR with competitors
Royalty Pharma (RPRX) five years free cash flow CAGR is 5.12%.